Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
New Product Enhancement and Four Scientific Presentations to Highlight Cleerly's Presence at the 75th Annual Scientific Session & Expo of the...
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
New Product Enhancement and Four Scientific Presentations to Highlight Cleerly's Presence at the 75th Annual Scientific Session & Expo of the...
Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification
Major Insurer Joins UnitedHealthcare, Cigna, and Humana in Covering Cleerly's AI-QCT Technology as Industry Momentum Builds with 86+ Million Lives...
Sixth late-breaking presentation from CONFIRM2 Registry demonstrates 12-fold risk gradient based on total plaque burden